BioXcel Therapeutics (BTAI) Expected to Announce Earnings on Thursday

BioXcel Therapeutics (NASDAQ:BTAI) is expected to be issuing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.58) per share and revenue of $0.1520 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, April 3, 2026 at 9:30 AM ET.

BioXcel Therapeutics Trading Down 2.6%

NASDAQ:BTAI opened at $1.47 on Tuesday. The stock has a 50 day moving average of $1.65 and a 200-day moving average of $2.03. The firm has a market capitalization of $32.15 million, a PE ratio of -0.15 and a beta of 0.18. BioXcel Therapeutics has a 52 week low of $1.17 and a 52 week high of $8.08.

Institutional Trading of BioXcel Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Millennium Management LLC increased its stake in shares of BioXcel Therapeutics by 78.5% during the fourth quarter. Millennium Management LLC now owns 1,835,192 shares of the company’s stock valued at $2,936,000 after acquiring an additional 807,139 shares during the period. Geode Capital Management LLC lifted its position in BioXcel Therapeutics by 64.6% in the fourth quarter. Geode Capital Management LLC now owns 206,168 shares of the company’s stock worth $330,000 after purchasing an additional 80,928 shares during the period. Jane Street Group LLC bought a new position in BioXcel Therapeutics during the 4th quarter valued at $204,000. State Street Corp boosted its stake in BioXcel Therapeutics by 19.9% during the 4th quarter. State Street Corp now owns 63,218 shares of the company’s stock valued at $101,000 after purchasing an additional 10,500 shares in the last quarter. Finally, Man Group plc acquired a new position in shares of BioXcel Therapeutics during the 4th quarter valued at $91,000. 30.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BTAI. HC Wainwright reduced their price objective on BioXcel Therapeutics from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Zacks Research upgraded BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, March 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Wednesday, January 21st. Finally, Rodman & Renshaw initiated coverage on shares of BioXcel Therapeutics in a research report on Tuesday, March 17th. They set a “buy” rating and a $17.00 price target for the company. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $11.50.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.